Keyword: Olumiant (baricitinib)
Lilly CEO David Ricks has overhauled his team twice since he took over in January, and this time he's focusing on manufacturing, tech and R&D.
Eli Lilly’s RA med baricitinib had been pegged as one of 2017’s hottest launches—and a threat to Pfizer’s Xeljanz. Not anymore.
Eli Lilly beat sales estimates in the second quarter, but the pressure is on for the company to continue to innovate.
Eli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a drug the FDA rejected in April.
Investors were in the mood for good news from Eli Lilly—and they got a bit of it in its first-quarter earnings report, even as pipeline worries cast a cloud over the numbers.
After a big slowdown in 2016, FDA new drug approvals got off to a hot start in 2017.
Eli Lilly and partner Incyte have received a complete response letter for their highly anticipated rheumatoid arthritis drug baricitinib.
The world's best-selling drug, AbbVie's Humira, isn’t worth its current net price—and isn’t as good at its job as two potential competitors. That’s ICER's conclusion after reviewing rheumatoid arthritis meds.
Only 22 meds were greenlighted by the FDA in 2016, but no matter what tally the industry amasses this year, the crop will bring some would-be blockbusters and market disrupters.